Malignant News and Research

RSS

Cancer risk independent of folic acid supplementation

Folic acid supplementation does not increase or decrease the risk for cancer, suggests research published in The Lancet.

28 Jan 2013

Five genes hold key to meningioma make up

Research published in Science shows that mutations in five genes characterize most meningiomas.

28 Jan 2013

Researchers investigate acidity in solid tumors to determine if pH levels play a role in cell invasion

Researchers at Moffitt Cancer Center and colleagues at Wayne State University School of Medicine investigated the acidity in solid tumors to determine if pH levels play a role in cancer cell invasion in surrounding tissues.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Telomerase gene mutation immortalizes deadly skin cancer

About ten percent of all cases of malignant melanoma are familial cases. The genome of affected families tells scientists a lot about how the disease develops. Prof. Dr. Rajiv Kumar of the German Cancer Research Center together with Prof. Dr. Dirk Schadendorf from Essen University Hospital studied a family where 14 family members were affected by malignant melanoma.

28 Jan 2013

Researchers identify cancer-associated mutations

Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously found.

25 Jan 2013

New method allows controlled release of drugs; could help develop targeted treatments

Researchers have discovered a method that allows for the controlled release of an active agent on the basis of a magnetic nanovehicle.

25 Jan 2013

New study may help treat patients with multiple myeloma

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

25 Jan 2013

Study shows promising results for cancer treatment

The plasma membrane transporter SLC5A8 can inhibit the spread of tumours by decreasing the amount of the anti-apoptotic protein surviving in tumour cells.

25 Jan 2013

Biomedical engineers identify natural switch that controls breast cancer metastasis

With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread.

24 Jan 2013

Study may help predict which multiple myeloma patients will respond better to certain treatments

24 Jan 2013

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

23 Jan 2013

SMO and AKT1 mutations appear to drive about 15% of meningiomas

Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of brain tumors known as meningiomas, a finding that could lead to the first effective drug treatments for the tumors, report scientists from Dana-Farber Cancer Institute and the Broad Institute.

23 Jan 2013

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Inspra (eplerenone) has now been accepted by the All Wales Medicines Strategy Group (AWMSG) for use in adult patients with chronic heart failure (CHF) NYHA class II, in combination with standard optimal therapy...

22 Jan 2013

Golden nanoparticle starves cancer cell to death

How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.

21 Jan 2013

MRI ‘good accuracy’ for detecting residual breast cancer

Magnetic resonance imaging is superior to mammography for the detection of residual breast cancer after neoadjuvant chemotherapy, research confirms.

21 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

Study finds key association between Kallikrein 6 and malignant tumors

One of the most common types of brain tumors in adults, glioblastoma multiforme, is one of the most devastating. Even with recent advances in surgery, radiation and chemotherapy, the aggressive and invasive tumors become resistant to treatment, and median survival of patients is only about 15 months. In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and the malignant tumors.

18 Jan 2013

ELTD1 biomarker may help diagnose glioma

Researchers using sophisticated genetic testing techniques have identified a promising new biomarker for diagnosis of glioma—the most common type of malignant brain tumor, reports the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Jan 2013

Scientists identify new mechanism for schistosomiasis-bladder cancer connection

About 200 million people across 75 of the poorest countries in the world are now infected by the blood parasite Schistosoma haematobium (S. haematobium). The infection causes severe urogenital disease, but also causes bladder cancer in a number of patients and why this occurs is not clear.

17 Jan 2013

Malignant News and Research

Cancer risk independent of folic acid supplementation

Five genes hold key to meningioma make up

Researchers investigate acidity in solid tumors to determine if pH levels play a role in cell invasion

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Telomerase gene mutation immortalizes deadly skin cancer

Researchers identify cancer-associated mutations

New method allows controlled release of drugs; could help develop targeted treatments

New study may help treat patients with multiple myeloma

Study shows promising results for cancer treatment

Biomedical engineers identify natural switch that controls breast cancer metastasis

Study may help predict which multiple myeloma patients will respond better to certain treatments

New apatamer can boost therapeutic effect of cell-based vaccines

SMO and AKT1 mutations appear to drive about 15% of meningiomas

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Golden nanoparticle starves cancer cell to death

MRI ‘good accuracy’ for detecting residual breast cancer

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Study finds key association between Kallikrein 6 and malignant tumors

ELTD1 biomarker may help diagnose glioma

Scientists identify new mechanism for schistosomiasis-bladder cancer connection

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News